Invesco Ltd. Cuts Position in GSK plc (NYSE:GSK)

Invesco Ltd. trimmed its holdings in shares of GSK plc (NYSE:GSK - Free Report) by 67.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 7,606 shares of the pharmaceutical company's stock after selling 15,460 shares during the quarter. Invesco Ltd.'s holdings in GSK were worth $257,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in GSK. Dorsey & Whitney Trust CO LLC lifted its holdings in GSK by 2.5% during the fourth quarter. Dorsey & Whitney Trust CO LLC now owns 11,506 shares of the pharmaceutical company's stock valued at $389,000 after purchasing an additional 278 shares in the last quarter. GC Wealth Management RIA LLC lifted its stake in GSK by 2.6% in the 4th quarter. GC Wealth Management RIA LLC now owns 14,009 shares of the pharmaceutical company's stock valued at $474,000 after buying an additional 353 shares in the last quarter. Jacobi Capital Management LLC boosted its holdings in GSK by 3.9% in the 4th quarter. Jacobi Capital Management LLC now owns 10,403 shares of the pharmaceutical company's stock worth $352,000 after buying an additional 389 shares during the last quarter. Gladstone Institutional Advisory LLC boosted its holdings in GSK by 3.4% in the 4th quarter. Gladstone Institutional Advisory LLC now owns 12,221 shares of the pharmaceutical company's stock worth $413,000 after buying an additional 407 shares during the last quarter. Finally, CENTRAL TRUST Co increased its stake in GSK by 5.6% during the 4th quarter. CENTRAL TRUST Co now owns 7,756 shares of the pharmaceutical company's stock worth $262,000 after buying an additional 414 shares in the last quarter. Hedge funds and other institutional investors own 15.74% of the company's stock.

GSK Trading Down 1.0 %

Shares of GSK stock traded down $0.39 during mid-day trading on Wednesday, hitting $37.11. The stock had a trading volume of 5,029,444 shares, compared to its average volume of 4,766,196. The firm has a 50-day moving average of $37.72 and a two-hundred day moving average of $36.01. The firm has a market cap of $76.57 billion, a P/E ratio of 23.34, a price-to-earnings-growth ratio of 1.12 and a beta of 0.51. The company has a quick ratio of 0.52, a current ratio of 0.78 and a debt-to-equity ratio of 1.12. GSK plc has a 12-month low of $31.72 and a 12-month high of $45.93.

GSK (NYSE:GSK - Get Free Report) last issued its quarterly earnings data on Wednesday, April 30th. The pharmaceutical company reported $1.13 earnings per share for the quarter, topping the consensus estimate of $1.08 by $0.05. GSK had a return on equity of 48.59% and a net margin of 8.13%. The company had revenue of $10.06 billion during the quarter, compared to analyst estimates of $7.52 billion. During the same period in the prior year, the business posted $0.43 earnings per share. The firm's revenue for the quarter was up 2.1% compared to the same quarter last year. Sell-side analysts forecast that GSK plc will post 4.14 earnings per share for the current year.

GSK Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, July 10th. Investors of record on Friday, May 16th will be issued a $0.4216 dividend. This is a positive change from GSK's previous quarterly dividend of $0.39. This represents a $1.69 annualized dividend and a yield of 4.54%. The ex-dividend date of this dividend is Friday, May 16th. GSK's payout ratio is 86.60%.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on GSK. Hsbc Global Res raised GSK to a "strong sell" rating in a research note on Monday, April 28th. BNP Paribas began coverage on shares of GSK in a research note on Tuesday, April 15th. They set a "neutral" rating and a $35.25 target price on the stock. Morgan Stanley began coverage on shares of GSK in a research report on Wednesday, February 12th. They issued an "equal weight" rating for the company. Finally, StockNews.com upgraded shares of GSK from a "buy" rating to a "strong-buy" rating in a research report on Thursday, April 24th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and four have given a strong buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $40.58.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.